UNSPSC 51453501: Thiabendazole or tiabendazole

This classification denotes an antihelminthic agent with the molecular formula C10H7N3S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier N1Q45E87DT, chemically known as 2-(1,3-thiazol-4-yl)benzimidazole but more generally known as thiabendazole, which bears US NIH Compound Identifier 5430. European Medicines Agency schedules Tiabendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10996MIG.

The term THIABENDAZOLE is an International Non-Proprietary Name World Health Organization schedules thiabendazole in its Anatomical Therapeutic Chemical (ATC) Classification. Thiabendazole bears US NLM identifiers UMLS ID C0039832 and NCI Concept Code C873. SMILES: C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3.

UNSPSC 51453501 Thiabendazole or tiabendazole is a Commodity code that shows limited relevance to recent state and local procurement activity. The code nominally describes a specific anthelmintic pharmaceutical ingredient, but the opportunities posted under it in 2026 solicited naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals and OTC products, medical and first aid supplies, and direct-to-manufacturer prescription program capabilities—none of which are thiabendazole or tiabendazole formulations. The mismatch between the code's narrow pharmaceutical scope and the broad health-supply and pharmacy-program work actually being solicited suggests either tagging inconsistency or that this code is being used as a catch-all within health procurement systems. The issuing bodies include a county health department (Seminole County, Florida), a state HHS commission (Texas), a municipal fire department (City of Tampa), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota and including Oregon).

Geographic activity is concentrated in Florida, Texas, and the upper Midwest through the MMCAP cooperative. The most recent representative solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the county community health building; the City of Tampa's invitation to bid 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000, sheltered exclusively for certified Small Local Business Enterprises with a 5 percent bid discount; the Minnesota MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across state and local facilities; and the Texas HHS Commission RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs. The code reports no activity that directly tracks to its stated commodity definition.